Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-14 18:30:45 - browse：13

Johnson & Johnson sign — MARK RALSTON/AFP via Getty Images

WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.

J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.

The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

hotspot

WSS

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Wegovy’s successful heart trial raises vital question about weight loss

Wegovy trial has doctors encouraged over new possibilities

Police still searching for prisoner who escaped from NYC hospital

Maui's cultural, historic landmarks damaged in the devastating wildfires

Biden administration opens offers in Medicare drug price negotiations

leisure time

Wikipedia

leisure time

Alkermes shareholders re

Cybersecurity threat forces Lurie Children's to take systems offline

Medicare proposal to cover medical devices draws a mixed reaction

Covid misinformation case heads to Supreme Court

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Police still searching for prisoner who escaped from NYC hospital

Drug repurposing or repositioning? The language matters

Maui's cultural, historic landmarks damaged in the devastating wildfires

What does generative AI mean for health care? We asked experts

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

leisure time

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Why failed clinical trials don’t always spell doom for a new drug

Naloxone nonprofit donates 200,000 doses after FDA approval

For Cytokinetics, FDA rejection of heart drug would help, not hinder

American woman, child freed after being kidnapped in Haiti last month

Woodcock on FDA’s accelerated approval and her next chapter

entertainment

Wikipedia

hotspot

focus